Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Adc Therapeutics stock

Learn how to easily invest in Adc Therapeutics stock.

Adc Therapeutics SA is a biotechnology business based in the US. Adc Therapeutics shares (ADCT) are listed on the NYSE and all prices are listed in US Dollars. Adc Therapeutics employs 312 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Adc Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ADCT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Adc Therapeutics stock price (NYSE: ADCT)

Use our graph to track the performance of ADCT stocks over time.

Adc Therapeutics shares at a glance

Information last updated 2022-07-03.
Latest market close$8.54
52-week range$5.52 - $32.00
50-day moving average $8.25
200-day moving average $17.17
Wall St. target price$29.33
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.54

Buy Adc Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Adc Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Adc Therapeutics price performance over time

Historical closes compared with the close of $8.54 from 2022-07-01

1 week (2022-06-27) 6.48%
1 month (2022-06-03) 18.61%
3 months (2022-04-05) -42.02%
6 months (2022-01-05) -56.41%
1 year (2021-07-02) -64.68%
2 years (2020-07-02) -83.27%
3 years (2019-07-01) N/A
5 years (2017-07-01) N/A

Adc Therapeutics financials

Revenue TTM $80.4 million
Gross profit TTM $-125,478,000
Return on assets TTM -27.72%
Return on equity TTM -84.74%
Profit margin -242.69%
Book value $2.12
Market capitalisation $656 million

TTM: trailing 12 months

Adc Therapeutics share dividends

We're not expecting Adc Therapeutics to pay a dividend over the next 12 months.

Adc Therapeutics share price volatility

Over the last 12 months, Adc Therapeutics's shares have ranged in value from as little as $5.52 up to $32. A popular way to gauge a stock's volatility is its "beta".

ADCT.US volatility(beta: 1.95)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Adc Therapeutics's is 1.9545. This would suggest that Adc Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Adc Therapeutics overview

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B. V. , Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited.

Frequently asked questions

What percentage of Adc Therapeutics is owned by insiders or institutions?
Currently 52.345% of Adc Therapeutics shares are held by insiders and 45.829% by institutions.
How many people work for Adc Therapeutics?
Latest data suggests 312 work at Adc Therapeutics.
When does the fiscal year end for Adc Therapeutics?
Adc Therapeutics's fiscal year ends in September.
Where is Adc Therapeutics based?
Adc Therapeutics's address is: Biopole, Epalinges, Switzerland, 1066
What is Adc Therapeutics's ISIN number?
Adc Therapeutics's international securities identification number is: CH0499880968

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site